Clinical Trial Update: Abemaciclib for Bone and Soft Tissue Sarcoma With Cyclin-Dependent Kinase (CDK) Pathway Alteration [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating abemaciclib for bone and soft tissue sarcomas with CDK pathway alterations is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chondrosarcoma
• Osteosarcoma
• Soft Tissue Sarcoma

Drugs mentioned

• Abemaciclib (abemaciclib)

Snippet

Sponsor: Medical College of Wisconsin | Conditions: Chondrosarcoma, Osteosarcoma | Phase 2 | Status: RECRUITING